Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 591 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Efficacy of Sintilimab in the Adjuvant Treatment for Patients with Resected,... January 26, 2024 A Systematic Analysis of the Global Burden of Disease from 2010... April 20, 2022 Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in... March 3, 2021 4-Year-Old Boy Calls Police To Tell Them About His Toys, Cop... October 31, 2021 Load more HOT NEWS Cancer waiting times: Latest updates and analysis A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is... Virtual Reality Could Reduce Stress for Chemo Patients, Improving Cancer Outcomes ΥΓΡΗ ΒΙΟΨΙΑ: ΤΟ ΜΕΛΛΟΝ ΣΤΗ ΔΙΑΓΝΩΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ
